Abstract Number: 1175 • 2013 ACR/ARHP Annual Meeting
ABCG2 May Influence Risk Of Gout Through Extra-Renal Metabolic Pathways: Analysis Of The Effects Of The Q141K Variant On Serum Urate Responses To a Fructose Load
Background/Purpose: Genetic variation in ABCG2 is a major risk factor for hyperuricemia and gout. This gene encodes a high-capacity urate transporter expressed in the intestine,…Abstract Number: 1177 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Canakinumab Pre-Filled Syringe Versus Triamcinolone Acetonide In Acute Gouty Arthritis Patients
Background/Purpose: Canakinumab (CAN), a selective, fully human, monoclonal anti-IL-1β antibody has demonstrated long-term benefits in gouty arthritis (GA) patients (pts) by targeting the inflammatory pathway…Abstract Number: 1178 • 2013 ACR/ARHP Annual Meeting
Effect Of Febuxostat On Serum Urate Levels In Gout Subjects With Hyperuricemia and Moderate-To-Severe Renal Impairment: A Randomized Controlled Trial
Background/Purpose: Up to 20% of patients with hyperuricemia (serum urate [sUA] >6.8 mg/dL) and gout have moderate-to-severe renal impairment. Higher sUA (>8.5 mg/dL) may increase the…Abstract Number: 1179 • 2013 ACR/ARHP Annual Meeting
Colchicine Use and The Risk Of Myocardial Infarction Among Gout Patients: Interim Results From a VA Retrospective Cohort Study
Background/Purpose: Gout patients are at increased cardiovascular (CV) risk. Since atherosclerosis is an inflammatory process, anti-inflammatory strategies to reduce CV risk are currently being investigated.…Abstract Number: 1180 • 2013 ACR/ARHP Annual Meeting
Rising Burden Of Gout and Poor Management Of The Disease In The United Kingdom: A Nationwide Population Study
Background/Purpose: To describe the trends of epidemiology of gout and patterns of urate-lowering treatment in the UK general population from 1997-2012. Methods: We used the…Abstract Number: 1181 • 2013 ACR/ARHP Annual Meeting
The Effect Of Uric Acid Lowering Therapy In Preventing Comorbidity and Acute Attack Of Gout; A Retrospective Study
Background/Purpose: We evaluated the effect of uric acid lowering therapy (ULT) in reducing the new development of comorbidities and the frequency of acute attacks…Abstract Number: 1182 • 2013 ACR/ARHP Annual Meeting
The Performance Of a Diagnostic Rule For Acute Gouty Arthritis Without Joint Fluid Analysis: a Validation Study
Background/Purpose: The gold standard to diagnose gout is the identification of monosodium urate (MSU) crystals in joint fluid. In primary care gout is mostly diagnosed…Abstract Number: 1183 • 2013 ACR/ARHP Annual Meeting
The Treatment Of Gout In Relation To The 2012 Uric Acid Target Guidelines In The US Population
The Treatment of Gout in Relation to the 2012 Uric Acid Target Guidelines in the US Population Background/Purpose: Gout is a debilitating form of arthritis mediated…Abstract Number: 1184 • 2013 ACR/ARHP Annual Meeting
High Mobility Group Box 1 Plays a Role In Gouty Arthritis
Background/Purpose: High mobility group box 1 (HMGB1) is a crucial cytokine that mediated the response to infection, injury and inflammation. It is recently discovered that…Abstract Number: 1186 • 2013 ACR/ARHP Annual Meeting
Use Of High-Dose Allopurinol To Reach Serum Uric Acid Targets In Patients With Gout Across Multiple Countries
Background/Purpose: Allopurinol is the most commonly used urate-lowering therapy (ULT) in the world. Although allopurinol is FDA approved for up to 800 mg/d and EMEA…Abstract Number: 1187 • 2013 ACR/ARHP Annual Meeting
A Large-Scale, Multicenter, Prospective, Open-Label, 6-Month Study To Evaluate The Safety Of Allopurinol Monotherapy In Patients With Gout
Background/Purpose: Documentation of the safety profile of allopurinol at doses ≥300 mg/day is important for its ongoing use as first-line monotherapy or in combination with…Abstract Number: 1188 • 2013 ACR/ARHP Annual Meeting
An Assessment Of The Response Of Chronic, Occult, Synovial-Based Inflammation Of Gout To Serum Urate Lowering Therapy
Background/Purpose: We recently demonstrated that synovitis is present in the vast majority of patients with inter-critical gout and that the severity of this synovitis did…Abstract Number: 1191 • 2013 ACR/ARHP Annual Meeting
Low-Dose Anakinra Is Effective For The Prophylaxis Of Acute Episodes Of Inflammation In Severe Tophaceous Gout
Background/Purpose: anakinra has been used off-label for the treatment of severe episodes of acute inflammation (EAIs) in gout. Only a retrospective series of 3 patients…Abstract Number: 1192 • 2013 ACR/ARHP Annual Meeting
Pharmacovigilance Update On Pegloticase For Treatment Refractory Gout: United States Clinical Experience Demonstrates The Value Of Serum Uric Acid Monitoring As a Biomarker Of Risk and Efficacy
Background/Purpose: Pegloticase was approved in the US in late 2010 for patients with chronic gout refractory to xanthine oxidase inhibitors (XOIs). The clinical development program…Abstract Number: 1193 • 2013 ACR/ARHP Annual Meeting
Target Tophus Size and Complete Response Rates In Patients Treated With Open-Label Pegloticase For Chronic Gout Refractory To Conventional Therapy
Background/Purpose: Pegloticase, a methoxyPEG-conjugated mammalian recombinant uricase, has been approved in the US and EU for the treatment of chronic gout refractory to xanthine oxidase…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »